Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

For this latter group, the prognosis is very poor, according to AbbVie. Tepkinly (known as Epkinly in some markets) was approved for use in DLBCL on the back of the phase 1/2 EPCORE study ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy Botox Cosmetic, expanding its use beyond the face for the first time ...

AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The latest trading session saw AbbVie (ABBV) ending at $188.57, denoting a -0.99% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.02%.

For years, AbbVie's (ABBV) blockbuster rheumatoid-arthritis treatment, Humira, which launched in 2002, was the world's best-selling drug. Related: Analyst revises AbbVie stock price target on drug ...